What drives people away from medication for opioid use disorder?

What drives people away from medication for opioid use disorder?
The opioid epidemic is in its fourth and possibly deadliest wave, exacerbated by the COVID-19 pandemic and disproportionately killing people of color. Medications for opioid use disorder (MOUD)—including methadone, buprenorphine, and naltrexone—are effective in combatting the epidemic, but sorely underused. Philadelphia’s Department of Behavioral Health and Intellectual disability Services recently enacted a suite of policies to remove logistical, structural, and payment barriers to MOUD in the publicly-funded behavioral health system, but some facilities still do not use these medications.
To better understand MOUD barriers, Penn Leonard Davis Institute of Health Economics experts interviewed 25 executive directors of publicly funded treatment organizations in Philadelphia that adopted or did not adopt MOUD, finding that stigma towards medications and ideological beliefs about MOUD treatment contribute to non-adoption.

Related Keywords

Philadelphia , Pennsylvania , United States , Rebecca Stewart , Philadelphia Department Of Behavioral Health , Upenn Leonard Davis Institute Of Health Economics , Behavioral Health , Penn Leonard Davis Institute , Health Economics , பிலடெல்பியா , பென்சில்வேனியா , ஒன்றுபட்டது மாநிலங்களில் , ரிபேக்க ஸ்டீவர்ட் , பிலடெல்பியா துறை ஆஃப் நடத்தை ஆரோக்கியம் , பென் லியோனார்ட் டேவிஸ் நிறுவனம் ஆஃப் ஆரோக்கியம் பொருளாதாரம் , நடத்தை ஆரோக்கியம் , பென் லியோனார்ட் டேவிஸ் நிறுவனம் , ஆரோக்கியம் பொருளாதாரம் ,